Oral GLP-1 Pipeline 2026: Orforglipron Advances, Danuglipron Out
Pfizer's danuglipron is shelved after a liver-safety signal. Eli Lilly's orforglipron is the lead oral candidate. Here's where Rybelsus and the next wave of oral GLP-1s actually stand.
Key takeaways
Pfizer discontinued danuglipron in mid-2025 after a drug-induced liver injury signal in a phase 3 participant.
Eli Lilly's orforglipron is a once-daily oral small-molecule GLP-1 receptor agonist with pivotal phase 3 readouts in 2025-2026.
Rybelsus (oral semaglutide 7/14 mg) is the only FDA-approved oral GLP-1, currently indicated for type 2 diabetes — not weight loss.
Novo Nordisk has filed oral semaglutide 25 mg with the FDA for weight management; an approval decision is anticipated in 2026.
All injectable weight-loss leaders — Wegovy, Zepbound, Saxenda — remain unchanged; tirzepatide is a dual GIP/GLP-1, not a pure GLP-1.
Why the oral GLP-1 race matters in 2026
For most patients, the deciding factor between trying a GLP-1 medication and skipping it is not price or efficacy — it is the needle. An estimated one in four adults reports significant injection hesitancy, and survey data from diabetes registries consistently show that oral options reach a broader population than self-injected therapies. That is why every major incretin manufacturer is now competing to bring a once-daily pill to market that can rival the weight loss seen with Wegovy and Zepbound.
As of 2026, remains the only FDA-approved oral GLP-1 receptor agonist. It is indicated for type 2 diabetes, not weight management, and must be taken with no more than 4 ounces of plain water, on an empty stomach, at least 30 minutes before food, other beverages, or any other oral medications. That narrow window is a real-world adherence hurdle and a key reason small-molecule pills like orforglipron are so anticipated.
This article tracks where the oral GLP-1 pipeline actually stands going into late 2026 — what advanced, what failed, and what to watch next. GLP1Zoom doesn't prescribe or sell — we compare and redirect to licensed providers. Always defer to your prescriber on any dose, switch, or new starts.
Pfizer's danuglipron: discontinued in 2025
Danuglipron was Pfizer's lead oral GLP-1 candidate and, until 2025, one of the most-watched pipeline assets in metabolic medicine. It was a small-molecule, non-peptide GLP-1 receptor agonist designed for once- or twice-daily dosing. Pfizer had already deprioritized the twice-daily formulation in 2023 after a high rate of gastrointestinal side effects and elevated discontinuation in mid-stage trials.
In April 2025, Pfizer announced it was discontinuing development of danuglipron entirely after a participant in the once-daily dose-optimization program experienced a potential drug-induced liver injury that resolved after stopping the drug. Although the signal was a single case and the company described the liver-enzyme profile across the broader program as generally consistent with other approved GLP-1s, Pfizer concluded that the benefit-risk did not justify continuing the program in a crowded competitive landscape.
The practical takeaway: danuglipron is no longer in late-stage trials and is not coming to market. Patients waiting for a Pfizer oral GLP-1 should consider that pipeline closed for the foreseeable future. Pfizer has signaled it will continue evaluating other obesity-pipeline candidates, but none are at a near-term filing stage.
Orforglipron: Eli Lilly's lead oral candidate
Orforglipron is Eli Lilly's once-daily, oral, non-peptide small-molecule GLP-1 receptor agonist. Unlike Rybelsus, which is a peptide that requires an absorption enhancer and a strict empty-stomach window, orforglipron is designed to be taken without food or fluid restrictions. That single change could meaningfully improve real-world adherence if the molecule reaches the market.
Lilly has run a broad late-stage program — ACHIEVE in type 2 diabetes and ATTAIN in obesity — with multiple readouts staggered through 2025 and 2026. Phase 2 data published in The New England Journal of Medicine showed weight loss in the high-single to low-double-digit percentage range over roughly 9 months, with a side-effect profile dominated by mild-to-moderate nausea, diarrhea, constipation, and vomiting — similar in pattern to injectable GLP-1s.
Lilly has publicly indicated plans to submit orforglipron to the FDA for both weight management and type 2 diabetes, with the weight-management filing expected first. Approval timing depends on regulatory review, but industry analysts are watching late 2026 and 2027 as the realistic decision window. Until FDA action, orforglipron is investigational and not available outside clinical trials.
Class: oral small-molecule GLP-1 receptor agonist (not a peptide).
Dosing under study: once daily, no food or water restrictions.
Studied indications: chronic weight management and type 2 diabetes.
Status as of 2026: phase 3 data reported; FDA filings pending or under review.
Not yet FDA-approved — not available by prescription.
Rybelsus today: the only approved oral GLP-1
(oral semaglutide) is the only FDA-approved oral GLP-1 receptor agonist in the United States. It is approved for adults with type 2 diabetes to improve glycemic control alongside diet and exercise. It is not approved for chronic weight management — that indication for semaglutide is held by the injectable .
The labeled strengths are 3 mg, 7 mg, and 14 mg once daily. The 3 mg dose is a starter strength for tolerability and is not intended for ongoing glycemic effect. The FDA-approved administration instructions are strict: take the tablet with no more than 4 ounces of plain water, on an empty stomach, at least 30 minutes before the first food, beverage, or other oral medication of the day. Violating that window measurably reduces absorption.
Common adverse events seen in the PIONEER trial program were predominantly gastrointestinal — nausea, vomiting, diarrhea, and abdominal pain — usually dose-related and most common during dose escalation. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not take Rybelsus. Always confirm dosing, titration, and contraindications with your prescriber.
Oral semaglutide 25 mg for weight: the next FDA decision
Novo Nordisk has separately developed a higher-dose oral semaglutide formulation — 25 mg once daily — specifically for chronic weight management. The OASIS phase 3 program reported clinically meaningful weight reduction versus placebo over roughly 16 months, with a safety profile in line with other semaglutide products.
Novo has submitted a regulatory application to the FDA for oral semaglutide 25 mg for weight management. If approved, it would become the first oral GLP-1 indicated for obesity in the United States, expanding patient choice beyond injectables like Wegovy. Regulatory decisions in this space have varied in timing, so a 2026 action is plausible but not guaranteed.
Importantly, the same strict administration rules that apply to Rybelsus — small sip of water, empty stomach, 30-minute pre-meal window — are expected to apply to any approved 25 mg oral semaglutide weight-loss product. That is the key real-world differentiator that orforglipron, if approved, would not share.
What the injectable landscape still looks like
While oral options expand, the FDA-approved injectable weight-management landscape in 2026 is essentially three products: (semaglutide 2.4 mg weekly), (tirzepatide weekly), and (liraglutide daily). Tirzepatide is a dual GIP and GLP-1 receptor agonist — not a pure GLP-1 — which matters when comparing mechanisms and trial outcomes.
For type 2 diabetes, the equivalent injectables are (semaglutide weekly) and (tirzepatide weekly), plus older agents. Saxenda is approved for adolescents aged 12 and older with obesity (BMI at or above the 95th percentile) and is titrated from 0.6 mg up to 3.0 mg subcutaneously over roughly 4-5 weeks per the prescribing information.
In the STEP-1 phase 3 trial of semaglutide 2.4 mg for weight management, nausea was reported in roughly 44% of the active arm versus about 15% on placebo. In the SURMOUNT-1 trial of tirzepatide, nausea ranged roughly 24-29% across the 5, 10, and 15 mg arms. These numbers are useful context when comparing future oral-pill GI tolerability data — most oral GLP-1 trials show a broadly similar pattern but at different absolute rates depending on dose escalation.
Where compounded GLP-1s fit (and don't)
During the FDA-declared semaglutide and tirzepatide shortages, and became widely available through telehealth providers. The FDA declared the semaglutide shortage resolved in October 2024. The tirzepatide shortage status has been the subject of ongoing litigation and updated FDA notices, with the rules around compounding shifting accordingly.
Critically, compounded GLP-1s are not FDA-approved as finished products. They have not been evaluated by the FDA for safety, efficacy, or quality the same way an approved drug has. Some patients still legitimately access compounded versions through state-licensed pharmacies for clinical reasons such as documented intolerance to specific inactive ingredients, but the regulatory landscape continues to tighten as shortages end.
Oral compounded GLP-1 products — including oral semaglutide compounds and sublingual or troche formulations — carry the same caveat: NOT FDA-approved as finished products. Bioavailability of oral peptide GLP-1s is highly dependent on the formulation, and compounded versions have not been tested in the way Rybelsus was tested in the PIONEER trial program.
Telehealth access and DEA timelines
GLP-1 medications are not controlled substances, so the DEA telemedicine prescribing rules that affect stimulants and benzodiazepines do not directly limit GLP-1 prescribing. However, the broader telemedicine policy environment continues to evolve through rolling temporary extensions, and any change to remote prescribing infrastructure can indirectly affect how quickly patients get evaluated and started on therapy.
For oral GLP-1s specifically, telehealth has been a primary access channel because the medications are taken at home, do not require injection training, and require relatively standard lab monitoring (HbA1c, kidney function, sometimes lipase if pancreatitis risk is a concern). When oral semaglutide 25 mg or orforglipron eventually reach approval, expect a similar access pattern.
GLP1Zoom doesn't prescribe or sell — we compare and redirect to licensed providers. We do not endorse specific telehealth platforms; we compare the publicly listed prices, brand vs. compounded options, and consult fees so you can choose with full information.
What to watch through 2026 and 2027
The next 12-18 months are likely to define the oral incretin category for the rest of the decade. Three signals matter most: orforglipron's FDA decision and label scope, the oral semaglutide 25 mg weight-management decision, and any pricing or coverage announcements from major payers as new oral options enter the market.
Beyond Lilly and Novo, several earlier-stage oral GLP-1 and dual-agonist candidates from other manufacturers are in phase 1 or 2 testing. These would not realistically reach market before 2028 at the earliest, and many will not survive late-stage safety and efficacy hurdles — as the danuglipron story demonstrated.
For patients today, the practical advice is the same as it has been: work with your prescriber on an FDA-approved option that matches your medical history, insurance, and tolerance. Pipeline news is interesting, but a pill that does not yet exist on a pharmacy shelf cannot help with weight or glycemic control right now.
Orforglipron FDA action (weight first, then T2D) — possible late 2026 / 2027.
Oral semaglutide 25 mg weight-management decision — possible 2026.
Updates to FDA shortage and compounding status for semaglutide and tirzepatide.
Any new liver-safety or cardiovascular signals from late-stage oral GLP-1 trials.
Payer coverage and PBM formulary placement for new oral entrants.
Frequently asked questions
Is orforglipron available by prescription in 2026?
No. As of 2026, orforglipron is an investigational drug from Eli Lilly that has completed or is completing phase 3 trials. It has not received FDA approval and is not commercially available outside of clinical studies. Lilly has indicated it intends to submit orforglipron for both chronic weight management and type 2 diabetes; the weight indication is expected first. Until FDA action, no licensed pharmacy in the U.S. can legally dispense it. Talk to your prescriber about approved alternatives like Rybelsus, Wegovy, Zepbound, or Saxenda while orforglipron remains in regulatory review.
Why was danuglipron discontinued?
Pfizer discontinued danuglipron in 2025 after a participant in the once-daily dose-optimization program experienced a potential drug-induced liver injury that resolved after stopping the drug. Although it was a single case and the broader liver-enzyme profile was described as generally similar to other GLP-1s, Pfizer concluded the benefit-risk no longer justified continuing in a crowded competitive field. Earlier, the twice-daily formulation had been deprioritized in 2023 over gastrointestinal tolerability concerns. Danuglipron is no longer in late-stage trials and is not expected to reach market.
Is Rybelsus approved for weight loss?
No. Rybelsus is FDA-approved for adults with type 2 diabetes to improve glycemic control along with diet and exercise. It is not approved for chronic weight management. The same active ingredient, semaglutide, is approved for weight management as Wegovy, which is an injectable. Novo Nordisk has separately submitted a higher-dose oral semaglutide 25 mg formulation specifically for weight management, but that product is still under FDA review. Until approval, prescribing Rybelsus for weight loss would be off-label and is at the discretion of a licensed clinician.
How is Rybelsus supposed to be taken?
Per the FDA-approved label, Rybelsus is taken once daily on an empty stomach with no more than 4 ounces of plain water. You must wait at least 30 minutes before consuming any food, other beverages, or other oral medications. Taking it with more water, with food, or too close to other medications meaningfully reduces absorption and can reduce its effect. The typical pattern is to start at 3 mg daily for tolerability before titrating. Always defer to your prescriber for the exact dose, titration schedule, and monitoring plan that fits your situation.
Will orforglipron be as effective as Wegovy or Zepbound?
Direct head-to-head trials between orforglipron and Wegovy (semaglutide 2.4 mg) or Zepbound (tirzepatide) have not been fully reported as of 2026. Phase 2 and reported phase 3 data show meaningful weight loss with orforglipron, but cross-trial comparisons of weight-loss percentages are unreliable because patient populations, durations, and titration schedules differ. Tirzepatide is also a dual GIP and GLP-1 agonist, not a pure GLP-1, which changes the mechanism. Your prescriber is best positioned to weigh efficacy data against your medical history and tolerance once orforglipron is approved.
Are oral compounded GLP-1s a safe alternative?
Compounded GLP-1 products — including oral or sublingual semaglutide compounds — are NOT FDA-approved as finished products. They have not been evaluated by the FDA for safety, efficacy, or quality the way an approved drug like Rybelsus has been. Oral GLP-1 absorption is especially formulation-sensitive, so a compounded oral version may behave very differently from the approved tablet. Some patients still access compounded versions through state-licensed pharmacies, but anyone considering this route should review the risks and the legal status carefully with their prescribing clinician.
What injectable weight-loss GLP-1s are FDA-approved right now?
For chronic weight management in adults, the FDA-approved injectable options are Wegovy (semaglutide 2.4 mg weekly), Zepbound (tirzepatide weekly), and Saxenda (liraglutide daily, titrated 0.6 mg to 3.0 mg over about 4-5 weeks). Saxenda is also approved for adolescents 12 years and older with obesity. For type 2 diabetes, semaglutide is sold as Ozempic and tirzepatide as Mounjaro. Tirzepatide is a dual GIP and GLP-1 receptor agonist, not a pure GLP-1. These labels are unchanged by the oral pipeline news in 2026.
We cite primary sources — FDA-approved prescribing information (DailyMed), ClinicalTrials.gov registry IDs, and peer-reviewed publications — over secondary commentary. Every medical claim is re-checked at least every 6 months. Spot something wrong? Tell us. See our full editorial policy.